What is Tiziana Life Sciences Ltd?
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 72.52M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.